Leading medical diagnostics/research company releases new research-use-only
monoclonal antibody for the identification of prions in a variety of species
DEDHAM, Mass., Oct. 6 /PRNewswire/ -- Signet Laboratories, Inc., a leading
medical diagnostics/research company specializing in the development of
monoclonal antibodies and diagnostic assays for cancer, infectious disease,
and neurodegenerative disease, today announced the availability of Monoclonal
Prion Antibody 6D11, the newest addition to the neuroscience product line.
Prion diseases, or Transmissible Spongiform Encephalopathies (TSE), are
degenerative diseases of the nervous system caused by transmissible particles
that contain a pathogenic isoform of the prion protein, a normal constituent
of cell membranes. These fatal diseases can affect bovine (BSE, Mad cow),
sheep (Scrapie), deer and elk (CWD), and humans (vCJD). Although cross-
species transmission of prion diseases seems to be limited by a "species
barrier," the occurrence of bovine spongiform encephalopathy (BSE) and its
transmission to humans indicate that animal prion diseases can pose a
significant public health risk.
"The development of highly sensitive assays for ante mortem detection of
misfolded prions is a top priority for minimizing the spread of the disease,"
stated Joe Bertelsen, Neuroscience Product Manager for Signet Laboratories.
"Signet's new 6D11 antibody, in addition to Signet's existing prion antibody
panel, gives researchers a powerful tool for developing such screening
systems."
About Signet Laboratories, Inc.
Signet Laboratories, Inc. (Signet, Dedham, MA) is a leading medical
diagnostics/research company specializing in the development of monoclonal
antibodies and diagnostics assays for cancer, infectious disease, and
neurodegenerative disease. Signet was created in 1989 as a commercial spinout
of Johnson & Johnson's Cambridge Research Laboratories, Inc. (CRL, Cambridge,
MA).
The Company was founded to continue the mission originally established at
CRL -- the early detection and recurrence monitoring of patients with cancer,
infectious disease, and neurodegenerative disease. Signet has developed
patented technology for diagnosis and recurrence monitoring and for risk
assessment of asymptomatic patients in these areas. For more than a decade,
the Company has aggressively maintained licensing and development programs,
which are responsible for its broad patent and intellectual estate.
Contact Information
Company Contact Neuroscience Contact
Colleen Scott Joe Bertelsen
Signet Laboratories, Inc. Signet Laboratories, Inc.
180 Rustcraft Road 180 Rustcraft Road
Dedham, MA 02026 Dedham, MA 02026
Phone: 781.915.1404 Phone: 781.915.1402
Fax: 781.461.2456 Fax: 781.461.2456
cscott@signetlabs.com jbertelsen@signetlabs.com
SOURCE Signet Laboratories, Inc.
 back to top
Related links:
http://www.signetlabs.com
CONTACT:
Colleen Scott, +1-781-915-1404,
cscott@signetlabs.com, or Joe Bertelsen, +1-781-915-1402,
jbertelsen@signetlabs.com, both of Signet Laboratories, Inc.
|
